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Despite years of intense research in the field of adipokines and 
musculoskeletal system (1), there is still an open debate over the 
effect of certain adipokines, particularly leptin and adiponectin, 
on this system. Though, adipokine effects on bone turnover and 
density are still under deep investigation (2). 
The review by Kanazawa in this issue of Adipobiology af-
fords insights into the effect of adipokines in the skeleton (3). It 
is becoming increasingly evident that the role of adipokines in 
skeletal physiology should be considered in a broad context of 
bone-cartilage-fat- brain- immune interactions. Actually, mus-
culoskeletal system, immune response and energy metabolism 
are functionally related by a complex neuroendocrine circuit 
involving a plethora of factors and cells (4).  Kanazawa’s review 
points the finger initially on leptin, the forerunner of adipokine 
superfamily (5) and outline clearly the difficult to understand 
the effects of leptin on skeleton. This interpretation is in part 
due to discrepant findings observed in studies carried on in ro-
dents, depending on the strains. Depending on the administra-
tion route of leptin (centrally versus peripherally). Depending 
on dosage, body mass index, gender etc… What else might ac-
count for these discrepancies in the literature regarding leptin’s 
action on bone? It is also evident that while each of these ele-
ments may be contributory, none can explain fully the current 
state of conflicting evidence. To further complicate the situation, 
human clinical studies do not shed any light on these questions. 
In any case, there is a clear consensus that leptin modulates bone 
metabolism although there is a “healthy” debate regarding its 
influence on bone formation versus resorption (6). Kanazawa 
focuses also on adiponectin, the other “godfather” of the fam-
ily. In this case, also, the reader is making his logical deduction: 
adiponectin is sometimes good and sometimes bad. This con-
clusion is due to the fact that during long time adiponectin has 
been viewed as a “positive” adipokine for its insulin-sensitizing, 
anti-inflammatory (at least at cardiovascular level) and anti-
atherogenic effects in metabolic diseases. However, various re-
cent studies have clearly indicated that the axiom adiponectin 
= healthful adipokine, which was generally assumed a few years 
ago seems to be incorrect (7-9). Finally, Kanazawa reviewed also 
other so-called young members of the family, although they are, 
at present, not so young as they were. This review is a compre-
hensive work that will help Adipobiology readers to familiarize 
with intriguing and amazing effects of adipokines on musculo-
skeletal system. Beyond any doubt, the discovery of leptin ini-
tially and next of the other members of adipokine superfamily, 
has remarkably revolutionized our narrow view of adipose tissue 
as a simply and passive energy storage reservoir. Since the first 
publication on leptin by Friedman’s group in 1994 (10), thou-
sands of articles on adipokines have documented that adipose 
tissue is a dynamic endocrine organ contributing to systemic 
feedback loops integrating multiple peripheral organs with the 
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central nervous system and immune system. However, under-
standing of the actions of adipokines dealt with in this review 
is generally still too incomplete to generate well-supported 
therapeutic hypotheses. The rate at which their roles are being 
clarified nonetheless makes it certain that they, too, will soon be 
central to pharmacotherapeutic approaches to bone metabolism 
diseases.
Regardless, the current issue of Adipobiology moves us at least 
a step forward in our understanding of the complex role of adi-
pokines in controlling the dynamics between bone and adipose 
tissue. This work outline that the topic of adipokines as media-
tors of bone biology is under active investigation as attested to 
by an increasing number of articles recently published. The mor-
al of the story, as usual in scientific stories, is that future studies 
will be necessary to further dissect the intricate feedback loops 
existing among adipose tissue, bone and brain.
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